Sign In
Buy LUMO
$4.34
+0 (+0%)
At Close: Mar 10, 2025
AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO
02:38pm, Wednesday, 06'th Nov 2024
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.
03:51pm, Wednesday, 23'rd Oct 2024
NEW YORK , Oct. 23, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Lumos Pharma, Inc. (NASDAQ: LUMO) and its board of directors concerning the proposed ac
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders
03:31pm, Wednesday, 23'rd Oct 2024
NEW YORK , Oct. 23, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
10:28am, Wednesday, 23'rd Oct 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lumos Pharma, Inc. (NASDAQ: LUMO) to Double Point Ventures LLC for $4.25 per share in cas
AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an update
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
09:00am, Thursday, 15'th Aug 2024
AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will
Lumos Pharma, Inc. (LUMO) Q2 2024 Earnings Call Transcript
09:30pm, Thursday, 01'st Aug 2024
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Lisa Miller - Vice President, Investor Relations Rick Hawkins - Chief Executive Office
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
04:05pm, Thursday, 01'st Aug 2024
Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
04:05pm, Tuesday, 23'rd Jul 2024
AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second qua
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
04:05pm, Monday, 20'th May 2024
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyse
Lumos Pharma, Inc. (LUMO) Q1 2024 Earnings Call Transcript
03:10pm, Wednesday, 15'th May 2024
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Lisa Miller - Vice President, Investor Relations Rick Hawkins - Chief Executive Officer
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
04:15pm, Tuesday, 14'th May 2024
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achiev
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
02:51pm, Thursday, 09'th May 2024
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quart
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
04:05pm, Thursday, 18'th Apr 2024
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) t
